• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.

作者信息

Ji Yan, Jin Jin Y, Hyman David M, Kim Geoffrey, Suri Ajit

机构信息

PK Sciences, Novartis Institutes for BioMedical Research, East Hanover, New Jersey, USA.

Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.

出版信息

Clin Transl Sci. 2018 Jul;11(4):345-351. doi: 10.1111/cts.12540. Epub 2018 Feb 1.

DOI:10.1111/cts.12540
PMID:29392871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6039198/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d23/6039198/5d7b397f058e/CTS-11-345-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d23/6039198/5d7b397f058e/CTS-11-345-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d23/6039198/5d7b397f058e/CTS-11-345-g001.jpg

相似文献

1
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology.肿瘤学和免疫肿瘤学剂量探索中的挑战与机遇
Clin Transl Sci. 2018 Jul;11(4):345-351. doi: 10.1111/cts.12540. Epub 2018 Feb 1.
2
Making precision oncology the standard of care.使精准肿瘤学成为护理标准。
Lancet Oncol. 2017 Jul;18(7):835. doi: 10.1016/S1470-2045(17)30474-6.
3
What was wrong and might now go right with clinical trials for lupus?狼疮临床试验出了什么问题，现在又可能如何步入正轨？
Curr Rheumatol Rep. 2009 Aug;11(4):235-7. doi: 10.1007/s11926-009-0044-y.
4
Development of rational drug combinations with investigational targeted agents.研发具有研究性靶向药物的合理药物组合。
Oncologist. 2010;15(5):496-9. doi: 10.1634/theoncologist.2009-0262.
5
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus.剂量探索设计中的当前问题：对美国食品和药物管理局肿瘤卓越中心项目 Optimus 的回应。
Clin Trials. 2024 Jun;21(3):267-272. doi: 10.1177/17407745241234652. Epub 2024 Apr 3.
6
Early-drug development in the era of immuno-oncology: are we ready to face the challenges?免疫肿瘤学时代的早期药物研发：我们是否准备好应对挑战？
Ann Oncol. 2018 Aug 1;29(8):1727-1740. doi: 10.1093/annonc/mdy225.
7
Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.中国、日本和美国的肿瘤治疗药物：药代动力学特征、给药方案及研发策略
Clin Pharmacol Ther. 2019 Jun;105(6):1303-1320. doi: 10.1002/cpt.1352. Epub 2019 Feb 25.
8
A Tale of Two Trials.两项试验的故事
Arthritis Rheumatol. 2020 Aug;72(8):1256-1257. doi: 10.1002/art.41261. Epub 2020 Jun 19.
9
Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective.从全球监管视角看新型肿瘤免疫检查点抑制剂的临床研发和首次批准
Clin Pharmacol Ther. 2019 Mar;105(3):582-597. doi: 10.1002/cpt.1123. Epub 2018 Sep 12.
10
First-in-man and first-of-class-in-man clinical trials in oncology.肿瘤学领域的首次人体临床试验和同类首创人体临床试验。
Int J Clin Pharmacol Ther. 2009 Jan;47(1):68-70. doi: 10.5414/cpp47068.

引用本文的文献

1
Translational Model-Informed Dose Selection for Iruplinalkib, a Selective Oral ALK/ROS1 Tyrosine Kinase Inhibitor.用于选择性口服ALK/ROS1酪氨酸激酶抑制剂鲁普替尼的转化模型指导剂量选择。
Clin Transl Sci. 2025 Jul;18(7):e70287. doi: 10.1111/cts.70287.
2
An exposure-safety analysis to support the dosage of the novel AKT inhibitor capivasertib.一项支持新型AKT抑制剂卡匹西利剂量的暴露安全性分析。
Cancer Chemother Pharmacol. 2025 Mar 28;95(1):48. doi: 10.1007/s00280-025-04775-8.
3
A Bayesian Dynamic Model-Based Adaptive Design for Oncology Dose Optimization in Phase I/II Clinical Trials.

本文引用的文献

1
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response.帕博利珠单抗在实体瘤患者中的时间依赖性药代动力学及其与最佳总体反应的相关性。
J Pharmacokinet Pharmacodyn. 2017 Oct;44(5):403-414. doi: 10.1007/s10928-017-9528-y. Epub 2017 Jun 1.
2
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1.变构抑制剂 ABL001 能够实现对 BCR-ABL1 的双重靶向。
Nature. 2017 Mar 30;543(7647):733-737. doi: 10.1038/nature21702. Epub 2017 Mar 22.
3
Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis.
用于I/II期临床试验肿瘤学剂量优化的基于贝叶斯动态模型的自适应设计
Pharm Stat. 2025 Mar-Apr;24(2):e2451. doi: 10.1002/pst.2451. Epub 2024 Nov 10.
4
Moving the needle for oncology dose optimization: A call for action.推动肿瘤学剂量优化：行动呼吁。
Clin Transl Sci. 2024 Jun;17(6):e13859. doi: 10.1111/cts.13859.
5
Deep Learning Insights into the Dynamic Effects of Photodynamic Therapy on Cancer Cells.深度学习对光动力疗法对癌细胞动态效应的见解
Pharmaceutics. 2024 May 16;16(5):673. doi: 10.3390/pharmaceutics16050673.
6
Moving the needle for oncology dose optimization: A call for action.推动肿瘤学剂量优化：行动呼吁。
CPT Pharmacometrics Syst Pharmacol. 2024 Jun;13(6):909-918. doi: 10.1002/psp4.13157. Epub 2024 May 22.
7
Reporting on patient's body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review.报告乳腺癌患者最近临床试验中患者的体重指数（BMI）：系统评价。
Breast Cancer Res. 2024 May 22;26(1):81. doi: 10.1186/s13058-024-01832-7.
8
Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors.替雷利珠单抗治疗实体瘤或血液系统恶性肿瘤患者的临床剂量依据。
Clin Transl Sci. 2024 Mar;17(3):e13769. doi: 10.1111/cts.13769.
9
Utility and impact of quantitative pharmacology on dose selection and clinical development of immuno-oncology therapy.定量药理学在免疫肿瘤治疗的剂量选择和临床开发中的作用和影响。
Cancer Chemother Pharmacol. 2024 Apr;93(4):273-293. doi: 10.1007/s00280-024-04643-x. Epub 2024 Mar 2.
10
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.PACE 和 OPTIC 试验中慢性期慢性髓性白血病（CP-CML）患者的 ponatinib 剂量调整动态。
Leukemia. 2024 Mar;38(3):475-481. doi: 10.1038/s41375-024-02159-0. Epub 2024 Jan 29.
纳武利尤单抗的时变清除率与疾病动态的关联及其对暴露-反应分析的影响
Clin Pharmacol Ther. 2017 May;101(5):657-666. doi: 10.1002/cpt.656. Epub 2017 Mar 22.
4
Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma.阿替利珠单抗在转移性尿路上皮癌中的临床药代动力学和药效学
Clin Pharmacol Ther. 2017 Aug;102(2):305-312. doi: 10.1002/cpt.587. Epub 2017 Jun 9.
5
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy.纳武利尤单抗剂量选择：癌症免疫治疗的挑战、机遇和经验教训。
J Immunother Cancer. 2016 Nov 15;4:72. doi: 10.1186/s40425-016-0177-2. eCollection 2016.
6
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.卡博替尼用于晚期RET重排非小细胞肺癌患者：一项开放标签、单中心、2期、单臂试验。
Lancet Oncol. 2016 Dec;17(12):1653-1660. doi: 10.1016/S1470-2045(16)30562-9. Epub 2016 Nov 4.
7
Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science.提高临床药效学在肿瘤药物研发中的价值：定量药理学与转化科学的联盟
Clin Pharmacol Ther. 2017 Jan;101(1):99-113. doi: 10.1002/cpt.544. Epub 2016 Nov 25.
8
An FDA oncology analysis of immune activating products and first-in-human dose selection.美国食品药品监督管理局对免疫激活产品及首次人体剂量选择的肿瘤学分析。
Regul Toxicol Pharmacol. 2016 Nov;81:448-456. doi: 10.1016/j.yrtph.2016.10.002. Epub 2016 Oct 13.
9
Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs.经验教训：小分子靶向肿瘤药物的剂量选择。
Clin Cancer Res. 2016 Jun 1;22(11):2630-8. doi: 10.1158/1078-0432.CCR-15-2646.
10
Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy.将 3 + 3 设计搁置：在靶向治疗时代，更有效的肿瘤学剂量发现试验方法。
Clin Cancer Res. 2016 Jun 1;22(11):2623-9. doi: 10.1158/1078-0432.CCR-15-2644.